Comparing Diuretic and Afterload Reduction Treatments for HeartLogic Alerts in Heart Failure Patients A Phase 4 Study Monitoring Boston Scientific Device Users

What this Trial Is About

This research focuses on patients with congestive heart failure CHF who have a Boston Scientific pacemaker or defibrillator equipped with a HeartLogic sensor. The study aims to evaluate standard treatments for CHF when patients show elevated HeartLogic scores but have no new symptoms. It compares outcomes of observation, diuretic therapy, and afterload reduction therapy to understand the best approach for managing these alerts. Participants with elevated HeartLogic scores without symptoms will be randomly assigned to one of three groups observation only, a diuretic protocol, or an afterload reduction protocol. The diuretic protocol involves adjusting doses of medications like furosemide, torsemide, or bumetanide, with careful monitoring and dose adjustments over time. The afterload reduction protocol involves increasing or adjusting medications such as sacubitrilvalsartan, hydralazine, and isosorbide dinitrate. Treatment continues until symptoms develop or the HeartLogic alert resolves. During the study, participants will be monitored regularly to track changes in their HeartLogic scores, symptom development, and any heart failure events. Follow-up includes checks at 30, 60, and 90 days after a HeartLogic alert. Researchers will assess how many participants recover from HeartLogic alerts, develop symptoms, or require emergency or hospital visits related to heart failure. The total participation duration and ongoing monitoring aim to capture treatment effects and patient outcomes accurately.

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts